$1.34
+0.01
(+0.37%)▲
3.73%
Downside
Day's Volatility :6.51%
Upside
2.89%
26.78%
Downside
52 Weeks Volatility :56.0%
Upside
39.91%
Period | Co-diagnostics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -0.74% | 5.1% | 0.0% |
6 Months | 17.54% | 4.9% | 0.0% |
1 Year | 7.2% | 16.6% | 0.0% |
3 Years | -87.16% | 13.2% | -22.3% |
Market Capitalization | 42.6M |
Book Value | $2.27 |
Earnings Per Share (EPS) | -1.26 |
PEG Ratio | 0.0 |
Wall Street Target Price | 1.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -289.06% |
Return On Assets TTM | -25.0% |
Return On Equity TTM | -42.73% |
Revenue TTM | 9.1M |
Revenue Per Share TTM | 0.31 |
Quarterly Revenue Growth YOY | 1243.2% |
Gross Profit TTM | 28.7M |
EBITDA | -37.4M |
Diluted Eps TTM | -1.26 |
Quarterly Earnings Growth YOY | 0.31 |
EPS Estimate Current Year | -1.23 |
EPS Estimate Next Year | -1.13 |
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Next Quarter | -0.34 |
What analysts predicted
Upside of 11.94%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 39.9K | ↑ 420.9% |
Net Income | -6.3M | ↓ 9.88% |
Net Profit Margin | -15.7K% | ↑ 75113.61% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 215.0K | ↑ 438.63% |
Net Income | -6.1M | ↓ 3.23% |
Net Profit Margin | -2.8K% | ↑ 12891.09% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 74.6M | ↑ 34579.9% |
Net Income | 42.5M | ↓ 799.91% |
Net Profit Margin | 56.98% | ↑ 2880.16% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 97.9M | ↑ 31.3% |
Net Income | 36.7M | ↓ 13.7% |
Net Profit Margin | 37.45% | ↓ 19.53% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 34.2M | ↓ 65.04% |
Net Income | -14.2M | ↓ 138.84% |
Net Profit Margin | -41.61% | ↓ 79.06% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 991.5K | ↓ 97.1% |
Net Income | -35.3M | ↑ 148.15% |
Net Profit Margin | -3.6K% | ↓ 3522.06% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 602.0K | ↓ 57.05% |
Net Income | -5.8M | ↓ 73.73% |
Net Profit Margin | -956.11% | ↑ 606.91% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 197.8K | ↓ 67.14% |
Net Income | -8.9M | ↑ 54.96% |
Net Profit Margin | -4.5K% | ↓ 3552.76% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.5M | ↑ 1142.18% |
Net Income | -6.0M | ↓ 32.93% |
Net Profit Margin | -243.47% | ↑ 4265.4% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.6M | ↑ 44.69% |
Net Income | -14.7M | ↑ 145.34% |
Net Profit Margin | -412.82% | ↓ 169.35% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 252.7K | ↓ 92.89% |
Net Income | -9.3M | ↓ 36.55% |
Net Profit Margin | -3.7K% | ↓ 3271.54% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 161.1K | ↓ 36.26% |
Net Income | -7.6M | ↓ 18.39% |
Net Profit Margin | -4.7K% | ↓ 1032.72% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.6M | ↓ 66.69% |
Total Liabilities | 2.6M | ↑ 221.75% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.2M | ↑ 42.63% |
Total Liabilities | 478.1K | ↓ 81.7% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 71.2M | ↑ 3115.65% |
Total Liabilities | 4.5M | ↑ 849.8% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 160.0M | ↑ 124.65% |
Total Liabilities | 25.6M | ↑ 462.89% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 123.1M | ↓ 23.09% |
Total Liabilities | 8.6M | ↓ 66.48% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 103.6M | ↓ 15.79% |
Total Liabilities | 17.6M | ↑ 105.85% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 117.0M | ↓ 4.95% |
Total Liabilities | 6.4M | ↓ 25.67% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 112.8M | ↓ 3.59% |
Total Liabilities | 9.4M | ↑ 47.14% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 108.7M | ↓ 3.65% |
Total Liabilities | 9.2M | ↓ 1.89% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 103.6M | ↓ 4.63% |
Total Liabilities | 17.6M | ↑ 91.84% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 86.7M | ↓ 16.38% |
Total Liabilities | 8.3M | ↓ 52.83% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 80.7M | ↓ 6.89% |
Total Liabilities | 8.3M | ↓ 0.18% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.1M | ↑ 27.05% |
Investing Cash Flow | -380.3K | ↑ 100.91% |
Financing Cash Flow | 1.9M | ↓ 68.4% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.5M | ↑ 35.42% |
Investing Cash Flow | -435.2K | ↑ 14.44% |
Financing Cash Flow | 5.9M | ↑ 214.65% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 28.2M | ↓ 609.77% |
Investing Cash Flow | -5.8M | ↑ 1238.17% |
Financing Cash Flow | 19.7M | ↑ 234.44% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 41.1M | ↑ 45.86% |
Investing Cash Flow | 4.1M | ↓ 170.37% |
Financing Cash Flow | 450.4K | ↓ 97.72% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 6.6M | ↓ 84.01% |
Investing Cash Flow | -58.2M | ↓ 1519.19% |
Financing Cash Flow | -14.0M | ↓ 3215.91% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.5M | ↑ 37.15% |
Investing Cash Flow | -10.6M | ↓ 80.05% |
Financing Cash Flow | -482.2K | ↓ 60.39% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.2M | ↓ 5.27% |
Investing Cash Flow | 13.2M | ↓ 224.49% |
Financing Cash Flow | -555.7K | ↑ 15.25% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.6M | ↑ 26.59% |
Investing Cash Flow | 3.2M | ↓ 76.05% |
Financing Cash Flow | -166.3K | ↓ 70.07% |
Sell
Neutral
Buy
Co-diagnostics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Co-diagnostics Inc | 25.23% | 17.54% | 7.2% | -87.16% | 26.42% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Co-diagnostics Inc | 4.96 | NA | 0.0 | -1.23 | -0.43 | -0.25 | NA | 2.27 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Co-diagnostics Inc | Sell | $42.6M | 26.42% | 4.96 | 0.0% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Co-diagnostics Inc
Revenue is down for the last 3 quarters, 3.55M → 161.10K (in $), with an average decrease of 64.6% per quarter
Netprofit is up for the last 3 quarters, -14.67M → -7.59M (in $), with an average increase of 40.1% per quarter
In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 44.2%
In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 168.1%
Vanguard Group Inc
Renaissance Technologies Corp
BlackRock Inc
Geode Capital Management, LLC
Bridgeway Capital Management, LLC
Kestra Advisory Services, LLC
co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
Organization | Co-diagnostics Inc |
Employees | 155 |
CEO | Mr. Dwight H. Egan |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.34
+0.37%
Keyarch Acquisition Corp
$1.34
+0.37%
Connexa Sports Technologies Inc
$1.34
+0.37%
Us Value Etf
$1.34
+0.37%
First Wave Biopharma Inc
$1.34
+0.37%
Global X Msci Next Emerging
$1.34
+0.37%
Fat Projects Acquisition Corp
$1.34
+0.37%
Capital Link Global Fintech
$1.34
+0.37%
Applied Uv Inc
$1.34
+0.37%